deferoxamine has been researched along with Diabetes Mellitus, Type 2 in 15 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "After 8 weeks of type 2 diabetes induced by a combination of high-fat diet and low-dose streptozotocin, male control and diabetic animals were subjected to thromboembolic middle cerebral artery occlusion (MCAO) and randomized to vehicle, DFX, or tPA/DFX and followed for 14 days with behavioral tests." | 5.62 | Deferoxamine Treatment Prevents Post-Stroke Vasoregression and Neurovascular Unit Remodeling Leading to Improved Functional Outcomes in Type 2 Male Diabetic Rats: Role of Endothelial Ferroptosis. ( Abdelsaid, M; Abdul, Y; Dong, G; Ergul, A; Fagan, SC; Hafez, S; Jamil, S; Johnson, MH; Li, W; Ward, R; Wolf, V, 2021) |
| " The iron chelator deferoxamine dramatically inhibited PA-induced insulin resistance, and iron donors impaired insulin sensitivity by activating JNK." | 3.91 | Iron overload by transferrin receptor protein 1 regulation plays an important role in palmitate-induced insulin resistance in human skeletal muscle cells. ( Choi, SE; Cui, R; Jeon, JY; Kang, Y; Kim, HJ; Kim, TH; Lee, HJ; Lee, KW; Lee, SJ, 2019) |
| "After 8 weeks of type 2 diabetes induced by a combination of high-fat diet and low-dose streptozotocin, male control and diabetic animals were subjected to thromboembolic middle cerebral artery occlusion (MCAO) and randomized to vehicle, DFX, or tPA/DFX and followed for 14 days with behavioral tests." | 1.62 | Deferoxamine Treatment Prevents Post-Stroke Vasoregression and Neurovascular Unit Remodeling Leading to Improved Functional Outcomes in Type 2 Male Diabetic Rats: Role of Endothelial Ferroptosis. ( Abdelsaid, M; Abdul, Y; Dong, G; Ergul, A; Fagan, SC; Hafez, S; Jamil, S; Johnson, MH; Li, W; Ward, R; Wolf, V, 2021) |
| "Deferoxamine has been proposed as a potentially important therapy for individuals with NIDDM and mild elevations in serum ferritin." | 1.29 | No effect of deferoxamine therapy on glucose homeostasis and insulin secretion in individuals with NIDDM and elevated serum ferritin. ( Pyzdrowski, KL; Redmon, JB; Robertson, RP, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 5 (33.33) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, J | 1 |
| Obando, D | 1 |
| Liao, V | 1 |
| Lifa, T | 1 |
| Codd, R | 1 |
| Mielke, N | 1 |
| Johnson, S | 1 |
| Bahl, A | 1 |
| Fadladdin, YAJ | 1 |
| Xue, M | 1 |
| Zhang, X | 1 |
| Chen, J | 1 |
| Liu, F | 1 |
| Xu, J | 1 |
| Xie, J | 1 |
| Yang, Y | 1 |
| Yu, W | 1 |
| Qiu, H | 1 |
| Xue, J | 1 |
| Jiang, J | 1 |
| Liu, Y | 2 |
| Shallom, SJ | 1 |
| Zelazny, AM | 1 |
| Giri, AR | 1 |
| Kaur, N | 1 |
| Yarrarapu, SNS | 1 |
| Rottman Pietrzak, KA | 1 |
| Santos, C | 1 |
| Lowman, PE | 1 |
| Niaz, S | 1 |
| Franco, PM | 1 |
| Sanghavi, DK | 1 |
| Zhu, D | 1 |
| Liang, R | 1 |
| Li, Z | 2 |
| Cheng, L | 1 |
| Ren, J | 1 |
| Guo, Y | 1 |
| Wang, M | 1 |
| Chai, H | 1 |
| Niu, Q | 1 |
| Yang, S | 1 |
| Bai, J | 1 |
| Yu, H | 1 |
| Zhang, H | 1 |
| Qin, X | 1 |
| Sahrakorpi, N | 1 |
| Engberg, E | 1 |
| Stach-Lempinen, B | 1 |
| Tammelin, TH | 1 |
| Kulmala, J | 1 |
| Roine, RP | 1 |
| Koivusalo, SB | 1 |
| Cheng, W | 1 |
| Pang, H | 1 |
| Campen, MJ | 1 |
| Zhang, J | 2 |
| Li, Y | 1 |
| Gao, J | 1 |
| Ren, D | 1 |
| Ji, X | 1 |
| Rothman, N | 1 |
| Lan, Q | 1 |
| Zheng, Y | 1 |
| Leng, S | 1 |
| Hu, Z | 1 |
| Tang, J | 1 |
| Dong, Q | 1 |
| Song, N | 1 |
| Qin, N | 1 |
| Chen, C | 1 |
| Sun, X | 1 |
| Easton, J | 1 |
| Mulder, H | 1 |
| Plyler, E | 1 |
| Neale, G | 1 |
| Walker, E | 1 |
| Li, Q | 1 |
| Ma, X | 1 |
| Chen, X | 1 |
| Huang, IC | 1 |
| Yasui, Y | 1 |
| Ness, KK | 1 |
| Hudson, MM | 1 |
| Robison, LL | 1 |
| Wang, Z | 1 |
| Subota, A | 1 |
| Spotswood, N | 1 |
| Roach, M | 1 |
| Goodarzi, Z | 1 |
| Holroyd-Leduc, J | 1 |
| Park, EA | 1 |
| Graves, SA | 1 |
| Menda, Y | 1 |
| Abdul, Y | 1 |
| Li, W | 1 |
| Ward, R | 1 |
| Abdelsaid, M | 1 |
| Hafez, S | 1 |
| Dong, G | 1 |
| Jamil, S | 1 |
| Wolf, V | 1 |
| Johnson, MH | 1 |
| Fagan, SC | 1 |
| Ergul, A | 1 |
| Cui, R | 1 |
| Choi, SE | 1 |
| Kim, TH | 1 |
| Lee, HJ | 1 |
| Lee, SJ | 1 |
| Kang, Y | 1 |
| Jeon, JY | 1 |
| Kim, HJ | 1 |
| Lee, KW | 1 |
| Leoncini, S | 1 |
| Rossi, V | 1 |
| Signorini, C | 1 |
| Tanganelli, I | 1 |
| Comporti, M | 1 |
| Ciccoli, L | 1 |
| Tajima, S | 1 |
| Ikeda, Y | 1 |
| Sawada, K | 1 |
| Yamano, N | 1 |
| Horinouchi, Y | 1 |
| Kihira, Y | 1 |
| Ishizawa, K | 1 |
| Izawa-Ishizawa, Y | 1 |
| Kawazoe, K | 1 |
| Tomita, S | 1 |
| Minakuchi, K | 1 |
| Tsuchiya, K | 1 |
| Tamaki, T | 1 |
| Tilbrook, L | 1 |
| Redmon, JB | 1 |
| Pyzdrowski, KL | 1 |
| Robertson, RP | 1 |
| Miyajima, H | 1 |
| Takahashi, Y | 1 |
| Kamata, T | 1 |
| Shimizu, H | 1 |
| Sakai, N | 1 |
| Gitlin, JD | 1 |
| Takahara, N | 1 |
| Kashiwagi, A | 1 |
| Nishio, Y | 1 |
| Harada, N | 1 |
| Kojima, H | 1 |
| Maegawa, H | 1 |
| Hidaka, H | 1 |
| Kikkawa, R | 1 |
| Nitenberg, A | 4 |
| Ledoux, S | 4 |
| Attali, JR | 2 |
| Valensi, P | 4 |
| Paycha, F | 1 |
| Sachs, R | 3 |
| Antony, I | 2 |
| Cutler, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Influence of Liraglutide on Diastolic Cardiac Function and Myocardial Perfusion as Determined by Magnetic Resonance Imaging in Patients With Type 2 Diabetes: a Double-blind Randomized Parallel-group Trial[NCT02655770] | Phase 4 | 40 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for deferoxamine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
The many faces of the adamantyl group in drug design.
Topics: Adamantane; Animals; Antimalarials; Diabetes Mellitus, Type 2; Drug Design; Humans; Hypoglycemic Age | 2011 |
Topics: Adult; Aging; Aluminum; Alzheimer Disease; Animals; Anti-Bacterial Agents; Artemisia annua; Body Mas | 2022 |
3 trials available for deferoxamine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Oxidative stress, erythrocyte ageing and plasma non-protein-bound iron in diabetic patients.
Topics: Aged; Case-Control Studies; Deferoxamine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Eryt | 2008 |
Use of desferrioxamine in the treatment of aceruloplasminemia.
Topics: Ceruloplasmin; Deferoxamine; Diabetes Mellitus, Type 2; Female; Humans; Iron; Iron Metabolism Disord | 1997 |
[Response of the coronary arteries to cold test and flow velocity increase is improved by deferoxamine but not by L-arginine in diabetic patients].
Topics: Arginine; Blood Flow Velocity; Cold Temperature; Coronary Angiography; Coronary Artery Disease; Coro | 1997 |
10 other studies available for deferoxamine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Deferoxamine Treatment Prevents Post-Stroke Vasoregression and Neurovascular Unit Remodeling Leading to Improved Functional Outcomes in Type 2 Male Diabetic Rats: Role of Endothelial Ferroptosis.
Topics: Animals; Deferoxamine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Endothelial Cells | 2021 |
Iron overload by transferrin receptor protein 1 regulation plays an important role in palmitate-induced insulin resistance in human skeletal muscle cells.
Topics: Adult; Animals; Antigens, CD; Case-Control Studies; Cells, Cultured; Deferoxamine; Diabetes Mellitus | 2019 |
Iron reduction by deferoxamine leads to amelioration of adiposity via the regulation of oxidative stress and inflammation in obese and type 2 diabetes KKAy mice.
Topics: Adipose Tissue, White; Adiposity; Animals; Cell Size; Chelation Therapy; Cytochrome b Group; Cytokin | 2012 |
Cross talk between iron metabolism and diabetes.
Topics: Aged; Amino Acids; Arteriosclerosis; Chromium; Cytokines; Deferoxamine; Diabetes Mellitus; Diabetes | 2004 |
No effect of deferoxamine therapy on glucose homeostasis and insulin secretion in individuals with NIDDM and elevated serum ferritin.
Topics: Arginine; Blood Glucose; C-Peptide; Deferoxamine; Diabetes Mellitus, Type 2; Ferritins; Follow-Up St | 1993 |
Oxidized lipoproteins found in patients with NIDDM stimulate radical-induced monocyte chemoattractant protein-1 mRNA expression in cultured human endothelial cells.
Topics: Antioxidants; Cells, Cultured; Chemokine CCL2; Deferoxamine; Diabetes Mellitus, Type 2; Endothelium, | 1997 |
Coronary artery responses to physiological stimuli are improved by deferoxamine but not by L-arginine in non-insulin-dependent diabetic patients with angiographically normal coronary arteries and no other risk factors.
Topics: Adult; Antidotes; Arginine; Cold Temperature; Coronary Angiography; Coronary Vessels; Deferoxamine; | 1998 |
[Inhibition of iron-catalyzed oxidative reactions restores mathcing between coronary blood flow and myocardial metabolic demand in type 2 diabetes].
Topics: Adult; Chelating Agents; Coronary Vessels; Deferoxamine; Diabetes Mellitus, Type 2; Endothelium; Fem | 2001 |
Coronary microvascular adaptation to myocardial metabolic demand can be restored by inhibition of iron-catalyzed formation of oxygen free radicals in type 2 diabetic patients.
Topics: Blood Flow Velocity; Blood Pressure; Cold Temperature; Coronary Angiography; Coronary Circulation; C | 2002 |
Deferoxamine therapy in high-ferritin diabetes.
Topics: Aged; Analysis of Variance; Blood Glucose; Body Weight; Cholesterol; Deferoxamine; Diabetes Mellitus | 1989 |